Le Lézard
Classified in: Covid-19 virus
Subjects: Photo/Multimedia, Corporate Social Responsibility, Webcast

Walgreens Boots Alliance Launches 2020 Corporate Social Responsibility Report


Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today launched the At the Heart of Health 2020 Corporate Social Responsibility (CSR) Report, which outlines the impact of its commitment to the critical needs facing communities today, including access to healthcare, diversity and inclusion accountability and innovative and sustainable solutions including reducing its carbon footprint and generation of waste while increasing re-use and recycling.

To mark the launch of the CSR Report, WBA ? along with host Bloomberg Media Brand Experiences ? will welcome industry and thought leaders to "Health and Humanity: Lessons from the Global Frontline," a virtual event that will touch on today's most pressing issues, from vaccine equity to diversity and inclusion to sustainability.

During the event, WBA will share how it continues to expand its role as a responsible corporate citizen through commitments to its four focus areas: healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace, and supports the communities it serves with equitable access to healthcare when they need it most.

"Helping people lead healthier, happier lives is at the heart of our business," said Ornella Barra, WBA's co-chief operating officer and the chairman of the company's Corporate Social Responsibility Committee. "For generations, it has been both our responsibility and a business imperative to operate as a force for good for people and the planet ? especially in times of crisis. Throughout the pandemic, we remain on the front line to ensure we safely provide healthcare services and support, which now includes COVID-19 vaccine administration, while also progressing in our other key CSR focus areas."

Highlights from 2020

In 2020, the company stepped up as a force for good to support its communities and made progress on its goals by:

WBA invites you to attend today's virtual event, "Health and Humanity: Lessons from the Global Frontline," beginning at 10 a.m. ET/9 a.m. CT. The event will feature experts on healthcare, diversity, equity and inclusion, sustainability and pharmacy and will touch on learnings from the pandemic and ways to make health systems more equitable and resilient for the future. Panelists include Alex Gorsky, Chairman and CEO of Johnson & Johnson; Jean-Paul Agon, CEO of L'Oréal; Valerie Jarrett, President, The Obama Foundation and Board Member of Walgreens Boots Alliance; and Dr. Sally Uren, OBE, CEO at Forum for the Future.

You can read more about WBA's Corporate Social Responsibility efforts here.

Notes to Editors:

About Walgreens Boots Alliance

Walgreens Boots Alliance (Nasdaq: WBA) is a global leader in retail and wholesale pharmacy, touching millions of lives every day through dispensing and distributing medicines, and through its convenient retail locations, digital platforms and health and beauty products. The company has more than 100 years of trusted health care heritage and innovation in community pharmacy and pharmaceutical wholesaling.

Including equity method investments, WBA has a presence in more than 25 countries, employs more than 450,000 people and has more than 21,000 stores.

WBA's purpose is to help people across the world lead healthier and happier lives. The company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. WBA is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business.

WBA is included in FORTUNE's 2020 list of the World's Most Admired Companies*, ranked first in the food and drugstore category. This is the 27th consecutive year that WBA or its predecessor company, Walgreen Co., has been named to the list.

More company information is available at www.walgreensbootsalliance.com.

*© 2020, Fortune Media IP Limited. Used under license.

(WBA-GEN)

Cautionary Note Regarding Forward-Looking Statements: All statements in this release and related virtual event that are not historical, including goals for and projections of future results, the expected execution and effect of our corporate social responsibility strategies and initiatives and the amounts and timing of their expected impact, are forward-looking statements that are based on current societal, market, competitive and regulatory expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including those described in Item 1A (Risk Factors) of our Form 10-K for the fiscal year ended August 31, 2020, our Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2020, and in other documents that we file or furnish with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially. These forward-looking statements speak only as of the date they are made. We do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: